cagrilintide phase 3 Novo Nordisk's CagriSema outperforms Ozempic in III trial Cagrilintide lowers bodyweight through brain

Originally derived from a protein found in the stomach, this peptide is designed to stimulate the bodys natural healing processes in a safe and targeted way

The injection vehicle is carefully selected to ensure compatibility with both active ingredients while maintaining appropriate pH, osmolality, and other physical characteristics necessary for subcutaneous administration

Additionally, while a plateau in weight loss was observed in the placebo group at week 18, weight-loss with cagrilintide continued throughout the 26 weeks

Although research remains at the preclinical animal stage, the product has become an important tool for dissecting glucose metabolism disorders and diabetes and developing novel hypoglycemic agents, with its key advantage lying in nicotinamide pathway regulation and NAD+ stabilization